PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27593256-0 2016 Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma. Yttrium-90 28-38 keratin 20 Homo sapiens 73-78 15453924-1 2004 We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab standard therapy in 143 rituximab-naive patients with relapsed or refractory low-grade, follicular, or transformed CD20+ non-Hodgkin"s lymphoma (NHL). Yttrium-90 84-94 keratin 20 Homo sapiens 245-249 25596049-7 2014 Ibritumomab tiuxetan (Zevalin) is an anti-CD20 mouse monoclonal antibody labeled with Yttrium-90 (Y-90). Yttrium-90 86-96 keratin 20 Homo sapiens 42-46 16203814-1 2005 PURPOSE: Targeted radioimmunotherapy with yttrium-90 (90Y)-labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non-Hodgkin"s lymphoma. Yttrium-90 42-52 keratin 20 Homo sapiens 200-204 16091197-4 2005 Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well. Yttrium-90 108-112 keratin 20 Homo sapiens 61-65 23158095-3 2012 Radioimmunotherapy (RIT) with an anti-CD20 antibody linked to iodine-131 or to yttrium-90 has emerged as well-tolerated treatment after induction. Yttrium-90 79-89 keratin 20 Homo sapiens 38-42 17287964-5 2007 An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab. Yttrium-90 88-97 keratin 20 Homo sapiens 32-36 16540013-3 2006 90Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttrium-90 to the malignant B-cells. Yttrium-90 91-101 keratin 20 Homo sapiens 52-56 16304400-7 2005 Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well. Yttrium-90 117-121 keratin 20 Homo sapiens 70-74 15498146-1 2004 Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. Yttrium-90 39-49 keratin 20 Homo sapiens 190-194 11258413-1 2001 The purpose of this study was to investigate whether marrow radiation absorbed dose estimates predict haematotoxicity following radioimmunotherapy with an yttrium-90 labelled anti-CD20 monoclonal antibody in non-Hodgkin"s B-cell lymphoma (NHL). Yttrium-90 155-165 keratin 20 Homo sapiens 180-184 12663713-1 2003 PURPOSE: Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of tumor response in patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL). Yttrium-90 39-49 keratin 20 Homo sapiens 71-75 11877757-11 2002 Yttrium-90 ((90)Y)--anti-CD20, which has little (90)Y excretion from the body, demonstrated the injected dose per body weight to be more predictive of marrow toxicity than indium-111 ((111)In) tracer dosimetry methods in heavily pretreated patients, and showed maximal safety with standard mCi/kg therapy dosing. Yttrium-90 0-10 keratin 20 Homo sapiens 25-29 11762415-0 2001 Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin"s lymphoma. Yttrium-90 9-18 keratin 20 Homo sapiens 32-36 11587375-1 2001 Clinical trials of an yttrium-90 (90Y)-conjugated monoclonal antibody to CD20 in patients with relapsed B cell non-Hodgkin lymphoma (NHL) are reviewed. Yttrium-90 22-32 keratin 20 Homo sapiens 73-77 15045033-1 2004 This article will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin"s lymphomas. Yttrium-90 77-87 keratin 20 Homo sapiens 122-126 12837157-0 2003 Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin"s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. Yttrium-90 119-129 keratin 20 Homo sapiens 33-37 10561019-4 1999 Anti-CD20 antibodies radiolabeled with iodine 131 and yttrium 90 given at nonmyeloablative doses yield remissions in 75% to 80% of cases, including 35% to 40% complete remissions. Yttrium-90 54-64 keratin 20 Homo sapiens 5-9 9816191-0 1996 Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Yttrium-90 0-10 keratin 20 Homo sapiens 24-28